Metastasis remains the principle cause of mortality for breast cancer and presents a critical 14 challenge because secondary lesions are often refractory to conventional treatments. While specific genetic 15 alterations are tightly linked to primary tumour development and progression, the role of genetic alteration 16 in the metastatic process is not well-understood. To investigate how somatic evolution might contribute to 17 breast cancer metastasis, we performed exome, whole genome, and RNA sequencing of matched metastatic 18 and primary tumours from pre-clinical mouse models of breast cancer. Here we show that in a treatment-19 naïve setting, recurrent single nucleotide variants and copy number variation, but not gene fusion events, 20
Introduction 29
Metastatic breast cancer remains the leading cause of cancer-related death among women 1, 2 . Of the 30 1.7 million new cases of breast cancer diagnosed annually worldwide, approximately 30% of patients 31 diagnosed with localized disease eventually present with metastatic lesions in distant organs. While non-32 metastatic breast cancer has a 5-year survival rate of 99%, metastatic disease reduces 5-year survival to 33 only 25% 2 . Therapeutic strategies to treat localized disease such as molecular profiling and targeted therapy 34 have been increasingly successful, but patients with disseminated disease continue to face much worse 35 outcomes, as metastases are largely insensitive to such treatments 3, 4 . Therefore to improve outcome for 36 patients with advanced cancer, specific metastasis-targeted strategies will need to be developed, as will a 37 deeper understanding of the unique biological processes that occur during disease progression 4-6 . 38
Despite the importance of this process, relatively little is known regarding somatic events that drive 39 the metastatic cascade. The most commonly accepted hypothesis of tumour progression postulates that 40 mutations are acquired over time, resulting in heterogeneous primary tumour tissue composed of distinct 41 subclones 7 . According to this hypothesis, metastatic capability is induced when a subclone acquires all of 42 the necessary secondary genomic alterations to intravasate into the circulation, survive in circulation, arrest 43 and extravasate at a distant site, and colonize that distant organ 7,8 . However, while the primary tumour 44 genetic heterogeneity predicted by this model is widely accepted, evidence of somatic metastasis-driving 45 mutations is lacking 9-11 . Large-scale projects such as The Cancer Genome Atlas (TCGA) 12 have provided 46 a detailed inventory of oncogenic driver mutations, but no equivalent data set currently exists for metastatic 47 disease. Furthermore, data from our lab and the work of others suggest that metastasis may instead be driven 48 by dynamic epigenetic variation of gene expression programs [13] [14] [15] [16] [17] and there is increasing evidence to favour 49 a model of early metastatic dissemination, which is inconsistent with the somatic evolutionary hypothesis 18-50 20 . The difficulty of targeting such dynamic gene expression programs and preventing dissemination of cells 51 from clinically undetectable tumours obliges a deeper assessment of the existence of targetable metastasis-52 driving mutations. In this study we have shown that recurrent single nucleotide variants and copy number 53 variants, but not gene fusion events, occur spontaneously in the absence of therapeutic pressures and drive 54 breast cancer metastasis. Of note, we identified recurrent mutations in the Ras signalling pathway that 55 specifically promoted metastasis in vivo. 56
Results 57
Unique SNVs are enriched in metastases 58
To complement ongoing human tissue studies and understand the metastatic genomic landscape in 59 a treatment-naïve setting, we performed next generation sequencing on metastatic tissue from pre-clinical 60 3 mouse models of metastatic breast cancer ( Supplementary Fig. 1 ). In this study we focus on the luminal-61 like MMTV-PyMT (PyMT) and MMTV-Her2 (Her2) genetically engineered mouse models (GEMMs) of 62 metastatic breast cancer, which model the PI3K activation or the HER2 amplification seen in 42% or 20% 63 of breast cancer patients, respectively 12,21 . The PyMT model produces palpable primary tumours at a mean 64 latency of 60 days and pulmonary metastases at 100 days in 85% of mice 22 . The Her2 model , produces 65 mammary tumours at a mean latency of 100 days, and pulmonary metastases at 200 days in 60% of mice 23-66 25 . We crossed the PyMT model (FVB/NJ background) with five mouse strains (FVB/NJ, C57BL/6J, 67 C57BL/10J, CAST/EiJ, MOLF/EiJ) to more closely recapitulate the genetic heterogeneity of human 68 populations. Due to the latency and high variability of the Her2 (FVB/NJ background) model disease 69 progression compared with PyMT, this study only includes Her2 x FVB/NJ data and sequencing of tissues 70 from additional strains is ongoing ( Supplementary Fig. 1a ). 71
To investigate whether somatic mutations might contribute to metastatic progression, we performed 72 exome sequencing (exome-seq) of 53 and 12 paired primary tumour (PT) and lung metastases (LM) from 73 the PyMT and Her2 GEMMs, respectively ( Supplementary Fig. 1a ). Single nucleotide variant (SNV) 74 analysis was performed using three independent SNV-calling algorithms. Genes predicted to harbour SNVs 75 by each algorithm were intersected to identify a common set of potentially mutated genes. We identified 76 1202 exon SNVs in PT tissue and 1768 in metastatic tissue compared with normal strain-specific gDNA 77 sequence ( Supplementary Fig. 2a, b) . 78
Candidate metastasis-driving SNVs were defined by two criteria: 1) enrichment in metastatic tissue 79 but not in primary tumour and 2) presence within the metastatic seeding cell. To identify SNVs likely 80 present in the metastatic seeding cell, only those SNVs found in at least 60% of the metastatic lesion (variant 81 allele frequency between 0.3 to 0.5) were considered as potential metastasis-driver events. This cut-off 82 accounts for the infiltration of non-tumour cells but still requires a heterozygous mutation to be present in 83 at least 60% of the cells within the lesion. The comparison of LM sequences to matched PT identified 196 84 SNVs in 164 genes common to all 3 SNV calling algorithms ( Fig. 1a , Supplementary Fig. 2c & 85
Supplementary Table 1 ). The 196 genes were then screened to identify recurrently mutated codons. Five 86 genes (Kras, Shc1, Ccni, Mtch2, Snrk) were identified with recurrent mutations in the same codon, and 87 again were common to all three algorithms (Supplementary Table 1 and Fig. 1b, d) . 88
The SNV calls were then analysed for genes that were recurrently mutated in different codons. A 89 total of 147 genes were identified with mutations observed in only a single animal by all three algorithms. 90
Twelve genes were identified has having been recurrently mutated in different codons in independent 91 animals ( Supplementary Table 1 ). Finally, to prioritize genes for future analysis, RNA sequencing (RNA-92 seq) data was examined to validate SNVs in tissues analysed by both analyses. An additional instance of 93 4 the Shc1 mutated codon was identified, and a potential recurrent mutation in Rfx8 was found 94
( Supplementary Table 1 ). 95
Two genes, Kras and Shc1, had recurring metastasis-specific mutations in independent animals of 96 the PyMT cohort ( Fig. 1b, d ). Two PyMT animals carried the oncogenic activating Kras G12D mutations 97 ( Fig. 1b) , and an additional three PyMT animals carried different nucleotide substitutions all within the 98 proline 561 or 451 codon (isoform a or b respectively) of Shc1, resulting in P561S, P561T, or P561H ( Fig.  99 1d). For those samples with gDNA or RNA still available (4 out of 7), Sanger sequencing validated the 100 presence of Kras and Shc1 SNVs in the original metastatic tissues analysed by exome-and RNA-seq, and 101 in some cases in additional metastases from the same animal (Supplementary Table 2 ). The presence of 102 recurrent metastasis-enriched SNVs in several animals in the absence of therapeutic pressures suggests that 103 specific coding mutations may play a fundamental role in driving metastasis. 104
To expand the search for additional genes with recurrent metastasis-enriched mutations, we 105 screened RNA-seq data from a cohort of 42 matched primary tumours and metastatic pairs from 40 PyMT 106 and 2 Her2 animals ( Supplementary Figure 1a ). The RNA-seq data included 17 PyMT animals also 107 analysed by exome-seq plus an additional 25 independent animals (2 Her2 and 23 PyMT) (Supplementary 108 Figure 1a ). First, the 164 genes with high-probability SNVs identified by exome-seq were screened against 109 the RNA-seq data to validate exome-seq SNV predictions and identify additional animals with mutations 110 in these genes (Supplementary Table 1 & 2). For animals used in both analyses, the predicted SNVs 111 identified by exome-seq were validated by the RNA-seq data given the gene was transcribed, suggesting 112 that the exome-seq filtering criteria correctly identified bona fide SNVs. One additional metastasis-enriched 113 Kras mutation (Q61R; Fig. 1c ) and an additional mutation in Shc1 P561 (P561A; Fig. 1e ) were observed 114 in two animals from the RNA-seq-only cohort. Unexpectedly, in addition to a single metastasis-enriched 115
Ctnnb1 oncogenically-activating SNV (S45P) 26 observed in exome-seq data, RNA-seq data revealed three 116 more independent animals possessing metastasis-specific Ctnnb1 S45F SNVs and another two with Ctnnb1 117 point mutations that are also often observed in human tumours (K335N, N387K) (Supplementary Table 1 ). 118
Sanger sequencing validated the presence of the SNVs for Ctnnb1 exome-seq S45P and RNA-seq N387K 119 mutations ( Supplementary Table 2 ). Insufficient sample material prevented Sanger validation of the 120 remaining RNA-seq-identified SNVs. Overall, for samples with available material, the rate of validation 121 by Sanger sequencing for metastasis-specific SNVs was approximately 80% (8 out of 10) (Supplementary 122 Table 2 and Supplementary Fig. 1 ). Finally, Sanger sequencing of matched pairs of tumours and metastases 123 from an additional 22 animals not used for RNA-or exome-seq was used to survey for 11 of the SNVs 124 identified by exome-and RNA-seq. This analysis identified yet another Shc1 P561H mutation, but no 125 additional samples containing the other 10 mutations were found. 126
Copy number variation drives metastasis and reduces overall survival among human breast cancer 127 patients 128
Using the METABRIC sequencing dataset of human breast cancer primary tumours, we assessed 129 the relevance to human disease of genes possessing metastasis-enriched SNVs identified in the PyMT and 130
Her2 mouse models. This analysis revealed that many genes possessing SNVs in our preclinical mouse 131 models were amplified in human tissue, and 18% (23 out of 123 human orthologs) of such alterations were 132 significantly associated with poor patient outcome ( Fig. 1f and Supplementary Fig. 4 & 5) . 133
Since human primary tumours possessed gene amplification or deletion in addition to point 134 mutations, we analysed the PyMT primary tumour/metastasis exome-seq pairs for potential copy number 135 variations (CNVs) that may contribute to metastatic spread. To determine allele-specific gain or loss we 136 used only those samples generated from progeny of the FVB/NJ-PyMT outcross as their genomes contained 137 an FVB and non-FVB (C57BL/6J, C57BL/10J, CAST/EiJ, or MOLF/EiJ) allele that could be readily 138 differentiated. Therefore, pure FVB/NJ-PyMT and FVB/NJ-Her2 tumour/metastasis pairs were not 139 analysed due to the lower confidence of CNV calling on a homozygous genetic background. Based on these 140 criteria, we performed CNV analysis using exome-seq data from 30 of the primary tumour/metastasis pairs 141 in our cohort. We first identified CNV in primary tumours and metastases compared to normal, and then 142 analysed this data for metastasis-specific CNVs ( Supplementary Tables 3-7) . Amplification and deletion 143 events were primarily restricted to the F1 animals of crosses with C57BL/6J and MOLF/EiJ, with recurrent 144 metastasis-specific CNVs on chromosomes 2, 4, 9, and 10 ( Fig. 2a ). Examination of the putative CNVs 145 suggested that the C57BL/6J alleles were specifically lost in the F1 hybrids, while FVB/NJ alleles were 146 under-represented in most of the CNVs in the MOLF/EiJ F1 hybrids. In addition, the chromosome 4 and 9 147
CNVs overlap with regions of the genome we have previously demonstrated to harbour inherited metastasis 148 susceptibility genes 27-29 , suggesting these genomic intervals may contain important metastasis-associated 149 factors. The Genomic Regions Enrichment of Annotations Tool (GREAT) 30 was used to identify the genes 150 associated with recurrent metastasis-specific CNVs. 371 genes were associated with recurrent regions of 151 CNV in PyMT metastatic lesions, and 46 of these genes possessed CNVs in two or more outcross strains 152
( Supplementary Table 8 and Supplementary Fig. 4 ). The METABRIC dataset was then screened again to 153 assess if CNVs within any of the 46 genes were significantly associated with breast cancer patient survival. 154
The amplification of approximately 17% (8 out of 46) of the genes queried was significantly associated 155 with worse patient outcome, including EBAG9 and PKHD1L1, located on mouse chromosome 15 and 156 PEX2, and ZFHX4, located on mouse chromosome 2 ( Fig. 2b) , which are all located on human chromosome 157 6
Fusion genes are not enriched in metastases 160
In a large-scale analysis of 560 human breast cancer samples, Nik-Zainal et al. discovered frequent 161 variation in genomic structure in primary tumour tissue 31 . To identify any potential targetable gene fusion 162 events that may contribute to metastatic progression, we analysed the RNA-seq data ( Supplementary Fig.  163 1) using the deFuse algorithm to identify discordant paired end alignments and thus putative gene fusion 164 events specific to metastatic tissue 32 . To reduce false positive results, putative alternative splice events from 165 adjacent genes were excluded from the analysis to eliminate rare transcriptional read-through products. 166
Forty-four putative fusion transcripts were detected in the primary tumours by this analysis. Seventy-one 167 fusion transcripts were detected in the metastases, with 17 fusions in common with the primary tumours 168 and 54 unique to the metastatic lesions. The 54 metastasis-specific putative fusion events involved a total 169 of 85 genes. Sixteen genes were associated with putative fusion events in more than one animal or involved 170 genes with multiple fusion partners ( Fig. 3a ). However, manual curation of the putative recurrent fusion 171 events revealed that 7 of the 15 breakpoints occurred in regions of repetitive elements within introns or 172
UTRs, suggesting potential alignment artefacts. Moreover, for the highly expressed genes (Csn3, Trf), the 173 variant transcripts were represented at <1% of the total read count, suggesting that these transcripts were 174 either not required for maintenance of the metastatic lesions, rare aberrant transcripts, or were artefacts of 175 the RNA-seq/deFuse analysis. Supplementary Fig. 1a ). MOLF/EiJ and CAST/EiJ F1 animals were used for this 180 analysis as their genomes are significantly polymorphic compared to FVB/NJ, allowing for allele-specific 181 identification. SNVs predicted by exome-seq were confirmed in all of those animals also included in the 182 Table 2 ). Putative coding-related structural variants such as insertion-183 deletions (indels), inversions, and translocations were identified using the BreakDancer algorithm 33 by 184 limiting the analysis to within transcripts and requiring a minimum of three variant reads per sample 185 (Supplementary Table 9 ). The resulting gene fusions were found to be predominantly intrachromosomal 186 and tended to cluster within regions of gene families, suggesting potential alignment artefacts. To reduce 187 this potential artefact, a threshold of a minimum of 10 kb between putative fusion partners was introduced, 188 resulting in 18 putative fusion events involving 31 genes observed in either more than one animal or with 189 multiple fusion partners (Fig. 3b ). No overlap between the putative structural variants observed from the 190 deFuse and BreakDancer analysis was observed. All structural variations predicted by BreakDancer under 191 these conditions were intrachromosomal, and 11 of the 18 predicted recurrent structural variants occurred 192 7 between 2 members of the same gene family. Of the remaining seven, two of the remaining predicted 193 structural variation breakpoints were within repetitive elements at both sites ( Fig. 3b , pink loops). Two 194 additional predicted structural variations contained a repetitive element at one of the breakpoints (Fig. 3b,  195 tan loops), while three were within single copy sequence at both sites (Fig. 3b, blue loops) . These results 196 suggest that structural variation resulting in fusion transcripts does not play a significant role in the 197 metastatic progression of the MMTV-PyMT mammary tumour model. 198
WGS analysis (Supplementary

Single nucleotide variants drive metastasis 199
The presence of recurrent oncogenic mutations in Kras and Ctnnb1, in addition to the recurrent 200 mutations of the codon of Shc1, are consistent with a potential metastasis-driving function of these genes 201
in the PyMT mouse model. Interestingly, previous analysis of a panel of metastatic mouse mammary 202 tumour cell lines revealed recurrent mutation of Kras in several cell lines 34 . Moreover, SNVs within KRAS 203 in the primary tumours of the METABRIC data set, although rare (0.6% of patients), was significantly 204 associated with poor survival in human breast cancer (Fig. 4a, b ). Together, these observations suggest that 205 this signalling axis may play an important role not only in tumorigenesis, but also in metastatic progression 206 of human malignancies and therefore warrants further investigation. CTNNB1 and SHC1 were amplified 207 (0.3% and 22% of patients, respectively), but were not included in the targeted sequencing performed on 208 173 cancer-related genes in METABRIC. Therefore, the mutational burden for these genes in patient 209 primary tumours within this data set is unknown. We thus focused on Kras as a potential breast cancer 210 metastasis driver gene. Wildtype (WT) or Kras G12D constructs were expressed in two independent Kras 211 WT mouse mammary tumour cell lines: 4T1, which is derived from a spontaneous BALB/c mammary 212 tumour, and MET1, derived from the MMTV-PyMT model ( Supplementary Fig. 7a ) 34 . Kras WT-, Kras 213 G12D-, or control empty vector (EV)-transduced cells were implanted orthotopically in syngeneic mice 214 and primary tumour weight and the number of pulmonary metastases were assessed after four weeks. 215
Expression of Kras WT and G12D increased tumour burden compared to EV in the MET1 line and a small 216 but non-significant increase in tumour growth was also observed with the 4T1 line ( Fig. 4c, f) . Therefore, 217
to assess metastatic capacity specifically, the number of metastatic nodules (Fig. 4d, g) was normalized to 218 primary tumour weight for each mouse. This analysis revealed a significant increase in metastatic capacity 219 of Kras G12D-expressing cells compared to both Kras WT and EV cells in both lines (Fig. 4e, h) . To further 220 test how modulation of Kras G12D affects metastatic potential, we utilized the 6DT1 mouse mammary 221 cancer cell line that bears an endogenous homozygous Kras G12D mutation 34 . Despite the short-lived 222 effects of siRNA, knock down of Kras in 6DT1 cells reduced metastasis to the lungs in spontaneous 223 metastasis assays compared to a non-targeting siRNA control (Fig. 4i-k and Supplementary Fig. 7b ). This 224 result was significant before controlling for primary tumour weight, and trending after normalization 225 8 (p=0.1) ( Fig. 4j, k) . These results are consistent with a function for constitutively activated Kras as a 226 metastasis driver gene in breast cancer. 227
Discussion 228
Breast cancer metastasis is the primary cause of breast cancer related mortality, and due to the 229 disparate biology of metastatic lesions compared to the original tumour there are few options for clinical 230 intervention 4,5,35-38 . In this study we hypothesized that somatic evolution of the tumour cell genome may 231 drive metastasis and also may provide novel therapeutic targets. However, to date a robust sequencing 232 dataset of paired treatment-naïve primary and metastatic tumour samples that is large enough to identify 233 recurrent mutations genomic events is not available for such analysis. A key obstacle in this progress is the 234 difficulty of obtaining appropriate tissue samples. Metastatic lesions are usually not surgically removed, 235 and data obtained from resected lesions are usually confounded by the application of neo-adjuvant and 236 adjuvant therapies, which may select for events associated with treatment resistance rather than 237 metastasis 39 . Therefore, in this study we have used mouse models to overcome these limitations and as a 238 hypothesis generation and testing platform for subsequent validation and characterization in human 239 experimental systems. 240
Here we have performed exome, whole genome, and RNA sequencing on a total of 94 pairs of 241 treatment-naïve primary and metastatic tumours 21,40 of the luminal-like PyMT and Her2 genetically 242 engineered mouse models. Our analyses identified multiple recurring metastasis-specific SNVs in lesions 243 at high allele frequency in a treatment-naïve setting, indicating that the variants were likely present in the 244 metastatic seeding cell and drove metastasis from a subclone within the primary tumour. Indeed, we show 245 here that the recurrent Kras G12D mutation observed in metastatic lesion from 2 PyMT mice increases the 246 metastatic efficiency of mouse mammary cancer cell lines in an orthotopic implantation model. 247
Furthermore, by overlapping sequencing analysis of several tissues, 96% (47 out of 49) of SNVs identified 248 by Exome-seq were confirmed in an orthogonal method ( Supplementary Table 2 ). Taken together our data 249 support the Nowell hypothesis of tumour evolution as a driver of metastasis 7 . 250
Interestingly, unlike oncogenic driver mutations, we did not observe a high percentage of lesions 251 with mutations in any specific gene, suggesting that there may be many metastasis drivers, each contributing 252 a small fraction of the overall metastasis-driving function within a population. We did, however, observe 253 several SNVs located in genes functioning within the Ras signalling pathway. These SNVs were observed 254 in ~15% (14 (3-Kras, 5-Shc1, 6-Ctnnb1) out of 94) of the animals in this study, which implicates the Kras 255 pathway as an important metastasis signalling axis in this model. The KRAS G12D mutation is a well-256 studied oncogenic driver leading to the development of aggressive lung and colorectal cancers [41] [42] [43] . 257 9 However, KRAS is not considered a driver of human breast cancer development and therefore its 258 metastasis-specific recurrence in this model was unexpected 44 . Additionally, the exact role of the Shc1 259 P561X mutation is unknown, but the localization of this mutation to the SH2 domain of SHC1 is consistent 260 with activating function and warrants further investigation 45 . 261
The SNV data reported here also suggest that there may be many ways within metastasis-associated 262 pathways to activate a pro-metastatic function. The identification of Kras and Ctnnb1 as recurrently mutated 263 metastasis drivers was unanticipated due to the lack of association observed in human breast cancer. The 264 presence of known, well-studied activating mutations in these genes within metastasis-founding cells, 265 however, strongly implicates the Kras-Ctnnb1 signalling axis as a critical component of metastatic 266
progression, at least in the PyMT model system. The activation of the Ctnnb1 pathway has been previously 267 linked to breast cancer progression and thus our data corroborates the importance of this network 46 , and 268
suggests an additional therapeutic opportunity to intervene in metastasis establishment and progression. 269
We have also identified recurrent metastasis-specific regions of CNV that may contribute 270 metastatic spread. Several studies have shown divergent CNV between primary and metastatic tissue from 271 small patient cohorts 47-50 , and through our use of the treatment-naive PyMT animal model we have further 272
shown that these genomic alterations occur through natural tumour progression and can drive metastasis. 273
Additionally, our data identified several genes associated with metastasis-specific CNV that, while 274 distributed across the mouse genome, are all localized within human chromosome 8q. Amplifications on 275 chromosome 8q are associated with tumour progression and worse outcomes in many cancer types, 276
suggesting that our analysis appropriately captures genetic alterations observed in human patients 51-56 . This 277 association suggests that our strategy for the identification of metastasis-driving CNVs aligns with human 278 biology, revealing a robust tool for the identification of clinically-relevant metastatic drivers. We anticipate 279 that with additional pairs, strain-specific and driver-specific metastasis-driver CNVs will be distinguished. 280
In this study we compare the metastasis-specific genomic alterations from mouse models to human 281 sequencing data produced by the METBRIC study. Despite the large number of patients included in this 282 study, it is somewhat limited as it largely reports survival associated primary tumour CNVs, and only 173 283 genes underwent targeted sequencing 57,58 . As we continue to sequence subsequent mouse models of 284 metastatic breast cancer such as Her2, MMTV-Myc, and C3-Tag we anticipate additional human datasets 285 will become available for expanded mouse-to-human SNV comparisons. 286
In summary, by performing a survey of the genomic landscape of metastatic progression in two 287 preclinical mouse models, we have identified recurrent, clinically-relevant mutations in genes and pathways 288 that drive metastasis. Metastasis is the leading cause of cancer-related death in breast cancer patients, with 289 10 over 30% of breast cancer patients progressing to metastatic disease which currently averages just 25% 5-290
year survival. By using the strategy outlined here, the continued characterization of preclinical mouse 291 models of metastasis will provide further insight into the associations between clinical subtypes, primary 292 tumour drivers, and metastasis-driving genomic alterations, ultimately creating new opportunity for the 293 generation of metastasis-targeted therapies. were crossed with female wild type FVB/NJ mice. All female F1 progeny were genotyped by the 307 Laboratory of Cancer Biology and Genetics genotype core for the PyMT or Her2 gene and grown until 308 humane endpoint. Mice were euthanized using intraperitoneal Avertin to anesthetize followed by cervical 309 dislocation. Primary tumour, metastatic nodules, and normal (tail) tissue were isolated immediately 310 following euthanasia and snap frozen in liquid nitrogen. Tissue samples were then stored at -80°C. 311 312 gDNA isolation 313
Primary tumour tissue was ground on dry ice and small fragments were taken for gDNA isolation. Whole 314 metastases were used for gDNA isolation. Tissue was lysed using Tail Lysis Buffer (100 mM Tris-HCl pH 315 8.0, 5 mM EDTA, 0.2% SDS, 200 mM NaCl, 0.4 mg/ml proteinase K) at 55⁰C overnight. Samples were 316 then placed in a shaking (1400 rpm) heat block for 1 hour at 55⁰C. RNaseA (Thermo Fisher Scientific) was 317 added (2 mg/ml final) and lysates were incubated on the bench for 2 minutes. gDNA was then isolated 318 using the ZR-Duet DNA/RNA MiniPrep kit (Zymo Research). 319 320 Sequencing and analysis 321 11 All analyses were carried out on the NIH Biowulf2 high performance computing environment. All analyses 322 were performed using software default parameters if not otherwise specified. 323 324
Exome sequencing 325
Exome sequencing was performed by the NCI Center for Cancer Research (CCR) Genomics Core and the 326 NCI Illumina Sequencing Facility. Exome libraries were prepared using an Agilent SureSelect XT Mouse 327
All Exon Kit for target enrichment. Libraries were barcoded and pooled before sequencing on an Illumina 328 HiSeq3000 or HiSeq4000 to an average depth of 40x. Samples were trimmed of adapters using 329
Trimmomatic software (0.39). The trimmed reads were aligned to the mm10 reference mouse genome using 330 BWA (0.7.17) or Bowtie (2-2.3.5.1) mapping software. SAMtools (1.9) mpileup, GATK (3.8-1) Mutect2, 331
and Strelka (2.7.1) were used to identify potential variants and the variants were filtered for known 332 polymorphisms from mgp.v5 (ftp://ftp-mouse.sanger.ac.uk/current_snps /mgp.v5.merged.snps_ 333 all.dbSNP142 .vcf.gz) and variants with Phred-scaled quality score of < 30 were removed. Annotation was 334 performed by Annovar (2018-04-16). High probability SNVs were identified after reads were visualized in 335 IGV and false positives were removed from the data. Select SNVs validated by Sanger sequencing 336 performed by the CCR Genomics Core. Copy number variation was performed for the F1 tumours using 337 the R (3.6.0) packages BubbleTree (2.15.0) and cn.mops (1.31.0), followed by filtering for metastasis-338 specific events and manual curation. We used BubbleTree to do allele-specific and strain-specific copy 339 number analysis, which required genotype data, and cn.mops for general copy number analysis, which 340 doesn't require F1 cross experiment data. The recurrent CNVs were defined as CNVs present in multiple 341 samples. 342 343
Whole genome sequencing 344
Library preparation was performed using the Illumina TruSeq DNA Sample Prep Kit FC-121-1001. 345
Samples were barcoded, pooled, and sequenced on an Illumina HiSeq4000 to a depth of ~10x per sample. 346
Samples were trimmed of adapters using Trimmomatic (0.39) software before the alignment. The trimmed 347 reads were aligned with the mm10 reference mouse genome mm10 using BWA alignment. SNV calls were 348 performed as described for exome sequencing. Structural variation analysis was performed using 349
BreakDancer (1.4.5), followed by filtering for metastasis-specific events and manual curation. For 350 breakpoints located within or near a gene, we filtered structural variations (SVs) by limiting the breakpoint 351 within 10 kb of a gene. CNV analysis was performed using cn.mops as described for exome sequencing. Virus transduction 390 1 x 10 6 293T cells were plated in 6 cm dishes 24 hours prior to transfection in P/S-free 10% FBS DMEM 391 media. Cells were transfected with 1 µg Kras or control expression plasmid and 1 µg of viral packaging 392 plasmids (250 ng pMD2.G and 750 ng psPAX2) using 6 µl of X-tremeGENE 9 transfection reagent 393 (Roche). After 24 hours of transfection, media was refreshed with complete DMEM. The following day, 394 virus-containing supernatant was passed through a 45-µm filter to obtain viral particles, which were then 395 transferred to 100,000 4T1 or MET1 cells. The viral media was removed and fresh complete DMEM was 396 added 24 hours post-transduction. Finally, the cells were selected with 10 µg/ml puromycin-or 5 µg/ml 397 blasticidin-containing complete DMEM beginning 48 hours after transduction. 
Western blotting 415
Protein lysate from 1 x 10 6 cells were extracted on ice using Golden Lysis Buffer (10 mM Tris pH 8.0, 400 416 mM NaCl, 1% Triton X-100, 10% Glycerol+Complete protease inhibitor cocktail (Roche), phosphatase 417 inhibitor (Sigma)). Protein concentration was measured using a BCA Protein Assay Kit (Pierce) and 418 analysed on the Versamax spectrophotometer at a wavelength of 560 nm. Appropriate volumes containing 419 20 µg of protein lysates combined with NuPage LDS Sample Buffer and NuPage Reducing Agent 420 (Invitrogen) were run on 4-12% (or otherwise indicated) NuPage Bis-Tris gels in MOPS buffer. Proteins 421 were transferred onto a PVDF membrane (Millipore), blocked in 5% milk (TBST + dry milk) for 1 hour 422 and incubated in the primary antibody (in 5% milk) overnight at 4°C. Membranes were washed with 0.05% 423 TBST (TBS + 5% Tween) and secondary antibody incubations were done at room temperature for 1 hour. 424
Proteins were visualized using Amersham ECL Prime Western Blotting Detection System and Amersham 425
Hyperfilm ECL (GE Healthcare). 426
427
The following primary antibodies were used: mouse anti-Actin (1:10,000; Abcam), mouse anti-myc-tag 428 (1:1000; Cell Signaling Technology), mouse anti-KRAS (1:1,000; Sigma). Secondary antibodies, including 429 goat anti-rabbit (Santa Cruz) and goat-anti-mouse (GE Healthcare), were used at a concentration of 430 1:10,000. 431 432
Statistics 433
Statistical significance between groups in in vivo assays was determined using the Mann-Whitney unpaired 434 nonparametric test using Prism (version 5.03, GraphPad Software, La Jolla, CA). Statistical significance 435 between samples in RT-qPCR analysis was determined by an unpaired t test, also using Prism. 436 437
Data Availability Statement 438
All sequence data that supports the findings of this study will be deposited in a public repository and the 439 accession codes will be made available prior to publication. 440 441 442 Figure 1. Recurrent metastasis-specific SNVs can be found at high allele frequency 585 a. Circos plots showing names and chromosomal location of genes identified by exome-and RNA-seq with metastasis-586 specific SNVs (orange: recurrent single strain, blue: recurrent in both strains, and black: singly mutated) from the PyMT 587 model (left) the Her2 model (right). b-e. IGV screen shots showing allele frequency in the blue and red boxes, representative 588 SNV reads, mutated codon letter, tissue type, and mouse strain. b, Exome-seq identified a C (blue) to T (red) SNV within 589
Kras resulting in the G12D amino acid substitution in metastases from two C57BL/6J x PyMT animals. c, RNA-seq 590 identified a T (red) to C (blue) SNV within Kras resulting in the Q61R amino acid substitution in a metastatic lesion from 591 one FVB/NJ x PyMT animal. d, Exome-seq identified C (blue) to T (red) and C (blue) to A (green) SNVs in metastases 592 from three animals (FVB/NJ, CAST/Ei (2 mets from 1 mouse with same SNV), and C57BL/6J x PyMT) resulting in the 593 P561S/T or H amino acid substitutions, respectively. e, RNA-seq identified a C (blue) to G (orange) SNV resulting in the 594 
